Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy

Guidelines on the out‐patient management of diabetic peripheral neuropathy have been developed from an international consensus meeting attended by diabetologists, neurologists, primary care physicians, podiatrists and diabetes specialist nurses. A copy of the full document follows this summary (Appe...

Full description

Saved in:
Bibliographic Details
Published in:Diabetic medicine 1998-06, Vol.15 (6), p.508-514
Main Authors: Boulton, A.J.M., Gries, F.A., Jervell, J.A.
Format: Article
Language:English
Subjects:
Ambulatory Care - methods
Biological and medical sciences
Diabetes. Impaired glucose tolerance
Diabetic Foot - therapy
Diabetic Neuropathies - diagnosis
Diabetic Neuropathies - therapy
diabetic neuropathy
diagnosis
Emergencies
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Humans
management
Medical History Taking
Medical sciences
Patient Education as Topic
Practice Guidelines as Topic
Risk Factors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Guidelines on the out‐patient management of diabetic peripheral neuropathy have been developed from an international consensus meeting attended by diabetologists, neurologists, primary care physicians, podiatrists and diabetes specialist nurses. A copy of the full document follows this summary (Appendix 1). The document arose out of suggestions from Neurodiab, a subgroup of the European Association for the Study of Diabetes, that there was a need for guidelines developed by consensus, for the outpatient management of patients with diabetic neuropathy. An international consensus group was created, chaired by two of the authors. A pilot working party met in 1995, followed by a full working party of 39 experts, neurologists and diabetes physicians (Appendix 2). This compiled a draft guideline document which was circulated to a number of international bodies. After consultation with its members, the final guidelines were approved by Neurodiab (chairman F.A. Gries) towards the end of 1997. © 1998 John Wiley & Sons, Ltd.
ISSN:0742-3071
1464-5491
1096-9136
DOI:10.1002/(SICI)1096-9136(199806)15:6<508::AID-DIA613>3.0.CO;2-L